- Home
- CNTX vs ACET Comparison
CNTX vs ACET Comparison
Compare CNTX & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- ACET
- Stock Information
- Founded
- CNTX 2015
- ACET 1947
- Country
- CNTX United States
- ACET United States
- Employees
- CNTX N/A
- ACET N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- ACET Health Care
- Exchange
- CNTX Nasdaq
- ACET Nasdaq
- Market Cap
- CNTX 75.6M
- ACET 69.9M
- IPO Year
- CNTX 2021
- ACET N/A
- Fundamental
- Price
- CNTX $1.26
- ACET $0.89
- Analyst Decision
- CNTX Strong Buy
- ACET Buy
- Analyst Count
- CNTX 7
- ACET 4
- Target Price
- CNTX $5.20
- ACET $6.00
- AVG Volume (30 Days)
- CNTX 500.2K
- ACET 2.9M
- Earning Date
- CNTX 11-10-2025
- ACET 11-10-2025
- Dividend Yield
- CNTX N/A
- ACET N/A
- EPS Growth
- CNTX N/A
- ACET N/A
- EPS
- CNTX N/A
- ACET N/A
- Revenue
- CNTX N/A
- ACET N/A
- Revenue This Year
- CNTX N/A
- ACET N/A
- Revenue Next Year
- CNTX N/A
- ACET N/A
- P/E Ratio
- CNTX N/A
- ACET N/A
- Revenue Growth
- CNTX N/A
- ACET N/A
- 52 Week Low
- CNTX $0.49
- ACET $0.45
- 52 Week High
- CNTX $2.46
- ACET $1.48
- Technical
- Relative Strength Index (RSI)
- CNTX 56.22
- ACET 49.86
- Support Level
- CNTX $1.19
- ACET $0.86
- Resistance Level
- CNTX $1.50
- ACET $1.07
- Average True Range (ATR)
- CNTX 0.15
- ACET 0.10
- MACD
- CNTX -0.02
- ACET -0.01
- Stochastic Oscillator
- CNTX 39.78
- ACET 32.80
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.